Home | Welcome to Contract Pharma   
Last Updated Sunday, October 26 2014
Print

Financial Reports: Roche



By Gil Roth



Published April 11, 2013
Related Searches: Pharma
Roche 1Q13

1Q Revenues: $12.5 billion (+4%)

1Q Earnings: not disclosed

Comments: Pharma revenues overall rose 5% to $9.9 billion, with U.S. sales up 13% to $4.2 billion, European sales up 1% to $2.5 billion, Japanese sales down 12% to $888 million, and rest-of-world sales up 6% to $2.3 billion. Rituxan sales were up 6% to $1.8 billion; Herceptin sales rose 11% to $1.7 billion and Avastin sales climbed 11% to $1.6 billion. Tamiflu sales were up 84% to $360 million in the quarter, and Actemra climbed 32% to $256 million.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On